{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02213705",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC Severe Systemic Sclerosis"
      },
      "Organization": {
        "OrgFullName": "Assistance Publique - Hôpitaux de Paris",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells",
      "OfficialTitle": "Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells",
      "Acronym": "MSC"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2020",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 6, 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "February 9, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 27, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 17, 2014",
      "StudyFirstSubmitQCDate": "August 7, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 11, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 15, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 19, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Assistance Publique - Hôpitaux de Paris",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "The main ailm of this phase I-II study is to evaluate toxicity and efficacy of allogenic mesenchymal stem cell therapy to treat severe systemic sclerosis. In practice this treatment will be given to patients with a rapidly evolutive disease or refractory to cyclophosphamide."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "SYSTEMIC SCLERODERMA",
          "ALLOGENEIC MESENCHYMAL STEM CELLS",
          "ADULT"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "SYSTEMIC SCLERODERMA",
          "TRANSPLANTATION",
          "ALLOGENEIC MESENCHYMAL STEM CELLS",
          "ADULT"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "toxicity",
            "PrimaryOutcomeDescription": "All grade 3 or above toxicity base on the CTCAE - Cancer Therapy Evaluation Program (CTEP), observed during the 2 years of follow up.\n\n(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf)",
            "PrimaryOutcomeTimeFrame": "2 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "survival",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "progression free survival",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Rodnan score",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Clinical response",
            "SecondaryOutcomeDescription": "Observed clinical response and efficiency in the scalability of SSc: 3, 6, 9 and 12 months after the procedure.",
            "SecondaryOutcomeTimeFrame": "3, 6, 9, 12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge> 18 years and <70 years.\nEstablished diagnosis of systemic sclerosis according to the criteria of the American College of Rheumatology\nSSc of poor prognosis, involving life-threatening with sever visceral impairment (cardiac, pulmonary or renal) AND \" a) contraindicating the use of or b) resistant to \" immunosuppressive therapy conventionally used in severe forms of the disease according to the European recommendations of EUSTAR (www.eustar.org) and EBMT (www.ebmt.org) which then rely on high doses of iv cyclophosphamide (either in monthly bolus at least six months or by intensification and autograft of Hematopoietic Stem Cells) or SSc with fibrosing lung damage threatening the vital prognosis which excludes a lung transplant.\n\nThese forms of severe and serious SSc WITH at least 6 months follow-up after completion of prior immunosuppressive therapy by high doses of iv cyclophosphamide when they were made, combine to varying degrees : rapidly progressive skin lesions with a score of Rodnan> 15 and one or more of the major visceral lesions defined as follows :\n\nRespiratory disease :\n\nDLCO <60% or FVC ≤70% of the theoretical value and the presence of interstitial lung disease (abnormalities on chest radiograph and / or lung HRCT with thin sections). It is necessary to ensure that non-related etiologies to scleroderma were eliminated; example: obstructive lung disease (chronic obstructive pulmonary disease or pulmonary emphysema). If the fibrosing lung disease threatens the vital prognosis, we will ensure of the exclusion of a possible lung transplant.\n\nAnd/or\n\nHeart disease:\n\ncongestive heart failure reversible, ventricular or atrial rhythm disturbances defined as recurrent episodes of atrial fibrillation or atrial flutter, recurrent paroxysmal atrial tachycardia or ventricular tachycardia, atrioventricular block of second or third degree, pericardial effusion with high abundance needing specific treatment of medical type (introduction of steroids) or surgical type (drainage). It is necessary to ensure that non-related etiologies to scleroderma were removed.\n\nSigned informed consent.\nPresence of a consenting intrafamilial MSC donor\nAffiliation to social security.\n\nExclusion Criteria:\n\nPregnancy or absence of appropriate contraception throughout the study.\nRespiratory Disease:\nsystolic Pulmonary arterial pressure (PASP)>55mmHg (on echocardiography or after right heart catheterization);\nDLCO <30% of the theorical ;\nRespiratory failure defined by oxygen arterial pressure at rest (PaO2) <8 kPa (<60 mmHg) and / or a blood pressure of carbon dioxide at rest (PaCO2)> 6.7 kPa (> 50 mmHg) without oxygen therapy.\n\nRenal Disease:\n\nCalculated creatinine clearance <20 ml/mn/m2\nSequelae cystopathy post treatment by cyclophosphamide\nHeart disease:\nClinical sign of a congestive heart failure refractory ;\nLeft ventricular ejection fraction <35% at myocardial scintigraphy or echocardiography;\nPulmonary arterial hypertension confirmed by right catheterization or suspected pulmonary hypertension with systolic PAP at echography > 40 mmHg\nChronic atrial fibrillation requiring oral anticoagulant therapy;\nUncontrolled ventricular arrhythmia;\nPericardial effusion with hemodynamic compromise assessed by echocardiography.\nHepatic Disease:\nHepatic impairment defined as a persistent increase in transaminases or bilirubin to 3 times normal.\nPsychiatric disorders, including drug taking and alcohol abuse.\nActive neoplasia or concomitant myelodysplasia, antecedent of neoplasia.\nBone marrow failure defined by neutropenia <0.5 x 109 / L, thrombocytopenia <50 x 109 / L, anemia <8 g / dL, CD4 lymphopenia <200 x 106 / L.\nUncontrolled systemic hypertension.\nUncontrolled acute or chronic infection, HIV1, 2 or HTLV-1, 2seropositivity.\nChronic hepatitis B or C active.\nSignificant exposure to bleomycin, toxic oils, vinyl chloride, trichloroethylene or silica; eosinophilia-myalgia syndrome, eosinophilia fasciitis.\nRisk of poor patient compliance.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "dominique farges, MDPHD",
            "OverallOfficialAffiliation": "APHP",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Saint-Louis Hospital",
            "LocationCity": "Paris",
            "LocationZip": "75010",
            "LocationCountry": "France"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000012595",
            "ConditionMeshTerm": "Scleroderma, Systemic"
          },
          {
            "ConditionMeshId": "D000045743",
            "ConditionMeshTerm": "Scleroderma, Diffuse"
          },
          {
            "ConditionMeshId": "D000012594",
            "ConditionMeshTerm": "Scleroderma, Localized"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M14564",
            "ConditionBrowseLeafName": "Scleroderma, Systemic",
            "ConditionBrowseLeafAsFound": "Systemic Scleroderma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M24713",
            "ConditionBrowseLeafName": "Scleroderma, Diffuse",
            "ConditionBrowseLeafAsFound": "Systemic Scleroderma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14563",
            "ConditionBrowseLeafName": "Scleroderma, Localized",
            "ConditionBrowseLeafAsFound": "Scleroderma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5565",
            "ConditionBrowseLeafName": "Systemic Scleroderma",
            "ConditionBrowseLeafAsFound": "Systemic Scleroderma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3490",
            "ConditionBrowseLeafName": "Localized Scleroderma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}